Haoyue Qin
Changsha, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial.
Journal: Nature communications
Published: September 13, 2025
Tumor immune microenvironment score predicts efficacy of immune checkpoint inhibitors-based regimens in advanced non-small cell lung cancer.
Journal: Journal of translational medicine
Published: August 14, 2025
Intrathecal nivolumab and IL-2 for treatment of leptomeningeal metastases in EGFR-mutated lung adenocarcinoma.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: February 18, 2025
Overall survival according to time-of-day of combined immuno-chemotherapy for advanced non-small cell lung cancer: a bicentric bicontinental study.
Journal: EBioMedicine
Published: October 16, 2024
Potential utility of albumin-bilirubin and body mass index-based logistic model to predict survival outcome in non-small cell lung cancer with liver metastasis treated with immune checkpoint inhibitors.
Journal: Chinese medical journal
Published: October 06, 2024
Toripalimab plus platinum-doublet chemotherapy as perioperative therapy for initially unresectable NSCLC: An open-label, phase 2 trial.
Journal: Med (New York, N.Y.)
Published: August 14, 2024
Intrathecal pemetrexed improves survival outcomes in previously treated EGFR-mutant advanced non-small-cell lung cancer with leptomeningeal metastases.
Journal: Heliyon
Published: March 26, 2024
Clinical treatment patterns, molecular characteristics and survival outcomes of ROS1-rearranged non-small cell lung cancer: A large multicenter retrospective study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: February 23, 2024
Octreotide plus IBI-318 plus anlotinib in the treatment of multiple neuroendocrine metastases of unknown primary lesions: a case report.
Journal: Frontiers in oncology
Published: February 23, 2024
Clinical outcomes for immune checkpoint inhibitors plus chemotherapy in non-small-cell lung cancer patients with uncommon driver gene alterations.
Journal: BMC cancer
Published: February 18, 2024
Clinical evidence for efficacy of pembrolizumab in MSI-H and TMB-H advanced solid tumor: results from three cancer centers in China.
Journal: Cancer immunology, immunotherapy : CII
Published: December 25, 2023
Last Updated: 09/26/2026